Trial Profile

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 21 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Proof of concept; Therapeutic Use

Most Recent Events

14 Nov 2023 According to a AIM ImmunoTech media release, Principal investigator and first author Shipra Gandhi of the Department of Medicine at Roswell Park, led the study under the scientific leadership of Pawel Kalinski.
14 Nov 2023 According to a AIM ImmunoTech media release, results from this trial were published in the Journal for ImmunoTherapy of Cancer.
17 Jul 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com